Vedolizumab for Injection

The full name of Vedolizumab is Vedolizumab for Injection, which is a humanized monoclonal antibody drug.

Vedolizumab for Injection is a humanized monoclonal antibody against human α4β7 integrin. After entering the body, it can specifically bind to α4β7 integrin, block the interaction between α4β7 integrin and mucosal cell adhesion molecules, and inhibit memory T-lymphocytes from entering the gastrointestinal tract. The drug is mainly used to treat chronic specific ulcerative colitis, Crohn’s disease and other diseases.

After administration, it can gradually replace glucocorticoid treatment, and the treatment effect is relatively good. However, during drug treatment, patients are prone to adverse reactions, such as dizziness, headache, nausea and vomiting, fever, fatigue, etc. A small number of patients may have complications of respiratory diseases such as nasopharyngitis, upper respiratory tract infection, and bronchitis. Some people with allergic constitutions may also be allergic to the drug and have a variety of allergic signs such as rash, skin itching, bronchospasm, etc. In severe cases, there is a possibility of suffocation and anaphylactic shock.

It is recommended to observe physical changes during medication. If adverse reactions and intolerance occur, the medication should be stopped immediately and medical consultation should be sought. If necessary, medication should be changed. During the treatment of related diseases, patients also need to strengthen personal life care, such as fixing the three meals a day, avoiding spicy and irritating foods, and paying attention to the combination of work and rest.